Valuation: Prothena Corporation plc

Market Cap 42Cr 38Cr 35Cr 32Cr 59Cr 4.01TCr 60Cr 419.08Cr 165.77Cr 2.09TCr 158Cr 154.62Cr 6.63TCr P/E 2026 *
70.8x
P/E 2027 * -8.2x
Enterprise Value 42Cr 38Cr 35Cr 32Cr 59Cr 4.01TCr 60Cr 419.08Cr 165.77Cr 2.09TCr 158Cr 154.62Cr 6.63TCr EV / Sales 2026 *
5.09x
EV / Sales 2027 * 20x
Free-Float
77.44%
Yield 2026 *
-
Yield 2027 * -
1 day+2.44%
1 week+0.60%
Current month+0.24%
1 month+1.33%
3 months-4.00%
6 months-21.86%
Current year-12.04%
1 week 7.93
Extreme 7.93
8.64
1 month 7.8
Extreme 7.8
9.3
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
41.54
5 years 4.32
Extreme 4.32
79.65
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Buy 10,000 0.0195%
08/10/26 Buy 90,000 0.1753%
02/10/26 Buy 1,00,000 0.1948%
Change 5-day change 1-year change 3-year change Capi.($)
+2.44%+0.60%-14.46%-78.83% 42Cr
+0.88%+1.18%+40.64%+74.91% 6.47TCr
-0.26%+7.23%+11.14%+74.78% 5.48TCr
+0.47%+5.10%+8.22%+101.52% 5.35TCr
-2.06%+2.51%+24.07%+50.98% 4.6TCr
-1.79%+0.49%+19.32%+122.77% 4.29TCr
-1.65%+3.34%+237.56%+819.04% 4.01TCr
-2.26%-2.06%+15.38%+45.14% 3.35TCr
+0.22%-4.77%+26.59%+0.55% 2.4TCr
+12.10%+18.47%+55.14%+45.58% 2.37TCr
Average +0.81%+1.82%+42.36%+125.64% 3.84TCr
Weighted average by Cap. +0.12%+2.58%+45.86%+149.63%

Financials

2026 *2027 *
Net sales 8.27Cr 7.4Cr 6.84Cr 6.19Cr 12Cr 786.86Cr 12Cr 82Cr 33Cr 411.55Cr 31Cr 30Cr 1.3TCr 2.1Cr 1.88Cr 1.74Cr 1.58Cr 2.95Cr 200.13Cr 3Cr 21Cr 8.28Cr 104.68Cr 7.9Cr 7.73Cr 331.44Cr
Net income 66.21L 59.2L 54.77L 49.59L 92.82L 63Cr 94.34L 6.59Cr 2.61Cr 33Cr 2.48Cr 2.43Cr 104.31Cr -5.41Cr -4.83Cr -4.47Cr -4.05Cr -7.58Cr -514.37Cr -7.7Cr -54Cr -21Cr -269.03Cr -20Cr -20Cr -851.83Cr
Net Debt - -
Projected Income Statement - Annual - Prothena Corporation plc
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
27/26/27 $8.400 +2.44% 5,94,543
23/26/23 $8.200 -0.61% 3,86,145
22/26/22 $8.250 +2.74% 3,81,831
21/26/21 $8.030 -5.53% 4,61,394
20/26/20 $8.500 +0.24% 5,29,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Prothena Corporation plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.200USD
Average target price
21.40USD
Spread / Average Target
+160.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Prothena Corporation plc
  1. Stock Market
  2. Stocks
  3. PRTA Stock